PRP for Hair Loss: Follow-up, Possible Reactions and Frequently Asked Questions

Why the course is not identical for every patient

PRP is not one standardized preparation. Tube system, processing, cellular composition, patient selection and clinical protocol vary between studies. A 2025 meta-analysis included 43 randomized controlled trials with 1,877 participants and still found substantial heterogeneity. There is therefore no universal PRP course that applies to every patient and every system. ^[1]

When can changes be assessed meaningfully?

Clinical studies use different follow-up time points. In one randomized half-scalp study, global photography and satisfaction assessments were obtained at baseline, three months and six months. Another randomized trial in women with androgenetic alopecia assessed outcomes including week 24. These are study time points, not individual guarantees, and they do not define one universal “result week.” ^{[2] [3]}

Which possible reactions have been reported?

Studies mainly report transient local effects. The 2025 meta-analysis found no statistically significant difference in overall adverse-event incidence versus the respective control groups. A randomized trial in women reported headache, scalp tightness, swelling, redness and post-injection bleeding. Older systematic reviews also note limitations in safety reporting, so rare events cannot be excluded reliably. ^{[1] [3] [4]}

Increased hair loss after PRP: normal shedding?

Hair loss that is noticed after PRP should not automatically be interpreted as a positive sign. Current literature does not establish temporary post-PRP shedding as a required event or a reliable predictor of later efficacy. Hair loss can fluctuate independently of PRP, and temporal association alone does not prove causality. ^[1]

Shedding is not an efficacy marker

Claims such as “the more hair falls first, the better the result later” are not adequately supported. Increased shedding is not an established efficacy marker. New, marked or persistent hair loss should likewise not automatically be dismissed as a positive expected response; the clinical situation may need reassessment.

How should follow-up be documented?

Subjective impressions vary considerably. More robust follow-up uses standardized baseline and follow-up data: comparable lighting, distance, camera angle, hair positioning and predefined scalp areas. Depending on the clinical question, trichoscopy or quantitative parameters such as hair density, hair count, terminal and vellus hairs or shaft diameter may also be recorded. ^[1]

More hairs, greater density and thicker hair are not the same

Outcome assessment must specify which endpoint is being measured. An increase in hair density does not necessarily mean that average hair diameter also improves. The 2025 meta-analysis reported moderate evidence for improvements in density and reduced hair loss, while consistent significant benefit was not shown for hair thickness and some other follicular parameters. ^[1]

Why before-and-after photographs alone can mislead

Lighting, hair length, moisture, styling, camera angle and parting position can materially change visual appearance. A dramatic before-and-after image is not the same as reproducible medical documentation. Clinical follow-up photographs should therefore be standardized whenever possible.

What if other measures are used at the same time?

If other interventions are started, stopped or changed at the same time, later change cannot reliably be attributed to one component. Trials study PRP alone, versus placebo, versus active treatments or in combination. These situations are not interchangeable, so relevant concomitant measures should be documented during follow-up. ^[5]

When should the baseline situation be reassessed?

Not all hair loss is androgenetic. New marked diffuse loss, a changed pattern, inflammatory scalp findings, newly localized patches or other unusual symptoms may justify reassessing the underlying cause rather than automatically attributing every change to PRP.

What does “no visible change” mean?

A lack of subjective visible change does not exclude a quantitative change, while a subjective impression of “more hair” does not prove an objectively measurable increase. A randomized split-scalp trial reported increased density from baseline on both PRP and placebo sides without a significant between-group difference, whereas other controlled studies reported differences favouring PRP. Individual studies and individual courses should not be interpreted in isolation. ^[6]

How safe is PRP for hair loss?

Controlled studies predominantly describe mild, transient local reactions. The systematic review by Cruciani et al. reported no serious PRP-related events but highlighted limitations in safety reporting. The larger 2025 meta-analysis likewise found no significant difference in overall adverse-event incidence versus controls. This should not be converted into a claim that PRP is “risk-free.” ^{[4] [1]}

Keep three questions separate

Conclusion: document the course rather than overinterpreting reactions

There is no universal point at which visible change must occur. Transient pain, redness, swelling or minor bleeding have been reported in trials. In contrast, supposed “shedding” should not automatically be presented as an expected or positive efficacy sign. Reproducible baseline and follow-up documentation is more informative than fixed timing promises.

This specialist article provides scientific and technical information. It is not an individual diagnosis, treatment recommendation or guarantee of outcome.

Related specialist articles